AMAG Pharmaceuticals, Inc.
$327.8K 8 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Life Spine, Inc.
Life Spine, Inc. reported $327,355.77 across General Payments, Research, and Ownership to 429 physicians and teaching hospitals across 429 transactions.
- $327.4K Above-median payer
- All-tracks total
- 429 Above-median volume
- Transactions
- 429 Above-median reach
- Recipients
- −$85.0K
- General Payments vs PY2023
Life Spine, Inc. reported $327,355.77 across all CMS Open Payments tracks (General + Research + Ownership) to 429 physicians and teaching hospitals in Program Year 2024 - ranking #873 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $327,355.77, averaging $763.07 per recipient.
Life Spine, Inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
26/100
Total payments
F
13/100
Transaction volume
F
13/100
Physician reach
F
13/100
Payment type diversity
D
63/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer life-spine-inc Life Spine, Inc.
$327.4K · #873/1,925 · 0.0% industry · PY2024
- TOT $327.4K
- RANK #873
- SHARE 0.0%
- TXN 429
- RCP 429
- CAT 5
- GEN $327.4K
- ΔGEN −$85.0K
- TOP1 11.3%
- PY 2024
Volume peers
Nearest volume peer: AMAG Pharmaceuticals, Inc. ($327.8K)
Life Spine, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Life Spine, Inc.'s CMS-reported General Payments decreased by $85.0K (−20.6%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: LIFE SPINE, INC.PY2023: LIFE SPINE, INC.PY2024: Life Spine, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $412,370.46
- PY2024
- $327,355.77
What the Data Shows for Life Spine, Inc.
The all-tracks total above combines three CMS reporting categories - General Payments, Research Payments, and Ownership/Investment interests - not one undifferentiated figure. For Life Spine, Inc. that figure is drawn almost entirely from the General Payments track (day-to-day consulting, meals, travel and speaking fees). CMS publishes each Program Year's data roughly 12 months after the reporting period ends, so this reflects the most recently released cycle; see our methodology for how the tracks are standardized and compared across companies.
The 5-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). The largest general-payment category is "Consulting Fee" at $225.0K, accounting for 68.7% of this company's General Payments and 124 transactions.
General Payment Breakdown by Type
Life Spine, Inc. made 5 types of general payments. "Consulting Fee" is the largest category at $225.0K, 68.7% of General Payments.
Life Spine, Inc. reports 5 general-payment categories - the top three are Consulting Fee (68.7%), Royalty or License (12.8%), and Travel and Lodging (11.2%). The remaining 2 categories make up 7.2% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Life Spine, Inc. divides its payments
General-payment categories, ordered by reported total
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $225.0K | 124 | 68.7% |
| Royalty or License | $42.0K | 15 | 12.8% |
| Travel and Lodging | $36.8K | 125 | 11.2% |
| Education | $14.1K | 10 | 4.3% |
| Food and Beverage | $9.5K | 155 | 2.9% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $128,652.23 (39.3%) of $327,355.77 in this company's General Payments records across 77 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Life Spine, Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Ali Mesiwala
$36,855.66 across 8 reported transactions
- 2
Sohrab Virk
$25,519.31 across 18 reported transactions
- 3
Francis Shen
$24,317.93 across 27 reported transactions
- 4
Steven Leckie
$21,168.00 across 41 reported transactions
- 5
Simon Chao
$20,791.33 across 19 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Life Spine, Inc. ranks #873 of 1,925 by total payments (top 45% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,276 of 1,838 by HHI (bottom 31% least concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- ImmunoGen, Inc. : $95.7K total payments, HHI 533
- TELA Bio, Inc. : $2.1M total payments, HHI 531
- Medistim USA, Inc. : $4.8K total payments, HHI 530
- Catheter Precision Inc. : $1.3K total payments, HHI 525
- Centinel Spine, LLC : $742.0K total payments, HHI 525
- Roche Diagnostics International Ltd : $376.3K total payments, HHI 524
- Life Spine, Inc. (this company) : $327.4K total payments, HHI 523
- Sarepta Therapeutics, Inc. : $2.8M total payments, HHI 522
- Exeltis, USA Inc. : $704.0K total payments, HHI 519
- EnableCV Inc. : $11.6K total payments, HHI 517
- Ostial Corporation : $8.4K total payments, HHI 515
- 3Shape Inc : $19.3K total payments, HHI 512
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Life Spine, Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Life Spine, Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Life Spine, Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Brainsway USA INC
$326.1K 242 recipients
Compare payment profiles
BioCryst Pharmaceuticals, Inc.
$326.1K 188 recipients
Compare payment profiles
Endogastric Solutions, Inc
$325.4K 933 recipients
Compare payment profiles
Delcath Systems
$329.6K 397 recipients
Compare payment profiles
Mindera Corp
$329.6K 6 recipients
Compare payment profiles
Put this to use
Life Spine, Inc. ranks #873 of 1,925 by all-tracks total payments, led by "Consulting Fee".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Consulting Fee" spend across every manufacturer, not just Life Spine, Inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.